PVX-410: PVX-410 is an investigational multi-peptide therapeutic cancer vaccine being developed for patients with triple negative breast cancer (TNBC) and patients with asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM). PVX-410 has the potential to work with the patient’s immune system by stimulating the patient’s cytotoxic T lymphocytes (CTLs) to target specific tumor-associated antigens which then attack the tumor. Learn more
MTAA-420: MTAA-420 is an investigational autologous multi-tumor antigen adoptive T cell (MTAA) therapeutic being developed initially for the treatment of multiple myeloma (MM). In the MTAA approach, the patient’s own T cells are stimulated and expanded ex vivo to target a proprietary peptide pool, which is highly expressed in MM and solid tumors. The T cells are then administered back to the patient where they have the potential to target the multiple antigens expressed on the patient’s tumor. Learn more
PVX-024/PVX-510 (2nd Generation Vaccines): OncoPep is currently exploring innovative technologies to enhance the first iteration of its vaccine as well as expand it to additional HLA subtypes, eg HLA-A24.
A clinical trial involves research using human volunteers (trial participants, including healthy volunteers or patients), and is intended to answer specific questions about potential new treatments for certain diseases. These studies allow us to evaluate whether these potential new treatments are safe and effective.
Visit www.clinicaltrials.gov to learn more about eligibility to participate in a study, risks and benefits of study participation, the informed consent process, questions to ask when considering whether to participate in a study, and much more information regarding clinical trials.
